Patent US4066762A successfully refreshed from Google Patents.
US4066762A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Derivatives of 7-(2-substituted-2-hydroxyiminoacetamido)-3-(1-substituted tetrazol-5-ylthiomethyl-3-cephem-4-carboxylic acid
Assignee: GlaxoSmithKline LLC
•
Filing: 1976-07-12
•
Granted: 1978-01-03
•
Expires: 1996-07-12
Abstract
Abstract New semisynthetic cephalosporins are described whose structures are characterized by having an alpha -oxyimino group in the 7-acetamido moiety and a sulfosubstituted tetrazolylthiomethyl group at position 3. The compounds are active antibacterial agents especially against Gram negative organisms.
Inventors
- 👤 George Lawrence Dunn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 13:21
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/44; C07D209/48; A; A61; A61P; A61P31/00; A61P31/04; C07D257/00; C07D257/02; C07D257/04
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
55 words
A compound of the formula: ##STR4## in which: R is thienyl, furyl or phenyl; R 1 is hydrogen, lower alkyl, benzyl, phenethyl, thienylmethyl or furylmethyl; n is selected from 0-9; R 2 is hydrogen or methyl; X is sulfo, sulfamyl, sulfamino or methylsulfonamido; and Y is hydrogen or methoxy, together with its alkali metal salts.
Claim 2
Dependent Claim
55 words
A compound of the formula: ##STR4## in which: R is thienyl, furyl or phenyl; R 1 is hydrogen, lower alkyl, benzyl, phenethyl, thienylmethyl or furylmethyl; n is selected from 0-9; R 2 is hydrogen or methyl; X is sulfo, sulfamyl, sulfamino or methylsulfonamido; and Y is hydrogen or methoxy, together with its alkali metal salts.
Claim 3
Dependent Claim
15 words
The compound is claim 1 in which the configuration at the imine center is syn.
Claim 4
Dependent Claim
10 words
The compound of claim 2 in which R is α-furyl.
Claim 5
Dependent Claim
15 words
The compound of claim 2 in which R 2 is hydrogen and n is 0-4.
Claim 6
Dependent Claim
36 words
The compound of claim 2 in which R is α-furyl, R 1 is hydrogen or methyl, Y is hydrogen or methoxy; R 2 is hydrogen; n is 0-4 and X is sulfo, sulfamyl, sulfamino or methylsulfonamido.
Claim 7
Dependent Claim
12 words
The compound of claim 2 in which X is sulfamino or methylsulfonamido.
Claim 8
Dependent Claim
15 words
The compound of claim 1 being 7-[syn-2-methoxyimino-2-α-furylacetamido]-3-[1-(2-sulfaminoethyl)-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid together with its sodium or potassium salts.
Claim 9
Dependent Claim
15 words
The compound of claim 1 being 7-[syn-2-methoxyimino-2-α-furylacetamido]-3-[1-(2-methanesulfonamido)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid together with its sodium or potassium salts.
Claim 10
Dependent Claim
10 words
The compound of claim 1 being 7-(syn-2-hydroxyimino-2-α-furylacetamido)-3-[1-sulfomethyltetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, disodium salt.
Claim 11
Dependent Claim
10 words
The compound of claim 1 being 7-[syn-2-methoxyimino-2-α-furylacetamidol]-3-[1-sulfomethyltetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid disodium salts.
Claim 12
Dependent Claim
10 words
The compound of claim 1 being 7α-methoxy-7β-[syn-2-methoxyimino-2-α-furylacetamido]-3-[1-sulfomethyltetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, disodium salt.
Claim 13
Dependent Claim
10 words
The compound of claim 1 being 7α-methoxy-7β-[syn-2-methoxyimino-2-α-furylacetamido]-3-[1-2-sulfaminoethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, disodium salt.
Claim 14
Dependent Claim
8 words
The compound of claim 1 being 7β-[syn-2-methyoxyimino-2-α-furylacetamido]-3-[1-(2-sulfamylethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.
Claim 15
Dependent Claim
22 words
The compound of claim 8 in the form of its 4-loweralkanoyloxymethyl esters said lower alkanoyl group having up to 6 carbon atoms.
Claim 16
Dependent Claim
23 words
A pharmaceutical composition having antibacterial activity comprising an active but nontoxic quantity of a compound of claim 1 and a pharmaceutically acdeptable carrier.
Claim 17
Dependent Claim
27 words
A method of inducing antibacterial activity in an infected patient comprising administering internally to said patient an effective but nontoxic quantity of a compound of claim 1.
Claim 18
Dependent Claim
11 words
The method of claim 16 in which the administration is parenterally.
Claim 19
Dependent Claim
24 words
The method of claim 16 in which the unit dosage quantity is selected from the range of from about 50-500 mg. of said compound.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-02 | 1981-07-04 | 1982-01-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-02 | 1985-07-04 | 1986-01-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-02 | 1989-07-04 | 1990-01-03 | $7700.00 | Window Closed / Lapsed |